, /PRNewswire/ — Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical companies seeking precision medicine solutions, today announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials.
Partnership provides revolutionary services facilitating rapid and reliable global clinical trial enrollment.
Aspyre Lung simplifies the detection of established non-small cell lung cancer (NSCLC) biomarkers by analyzing both DNA and RNA from tissue and blood using a streamlined four-step workflow. Designed to run on existing qPCR platforms, it integrates seamlessly into laboratories globally and aligns with CellCarta’s mission to support global clinical trials through innovative genomic services.
Under the terms of the strategic partnership agreement, CellCarta will set up and validate Aspyre Lung in their European laboratories first, followed by its US-based laboratories and will have non-exclusive rights to utilize Aspyre Lung for clinical trials globally. The partnership provides customers with revolutionary services leveraging both liquid …